News | Heart Valve Technology | July 14, 2015

Biotronik Announces Successful First Implantations of Resheathable Transcatheter Aortic Valve

Implantations in aortic stenosis patients confirm safety at 30 days after vascular intervention

July 14, 2015 - Biotronik announced the completion of the BIOVALVE first-in-human trial for its new transcatheter aortic valve. Study doctors successfully implanted the device in patients suffering from severe symptomatic aortic stenosis. The study, which established the transcatheter aortic valve implantation (TAVI) device's early safety at 30 days, was conducted at the University Heart Center Hamburg-Eppendorf (UKE), Germany.

The second-generation resheathable TAVI device is indicated for treating aortic stenosis. The most prevalent valvular heart disease, aortic stenosis is particularly common in those over the age of 75; around 1.2 million patients are diagnosed with this condition in Europe alone. Many of these patients are eligible for TAVI, a catheter-based procedure that replaces a patient's diseased native aortic valve with a bioprosthesis. To aid the implantation and improve patient safety, the Biotronik TAVI device allows for resheathability, meaning that, if necessary, the valve can be retracted into the delivery sheath, repositioned and redeployed in the correct position.

"Resheathability is an essential safety feature for this type of TAVI device," commented study investigator Ulrich Schäfer, M.D., UKE, Hamburg, Germany. "The Biotronik device examined in the BIOVALVE trial features resheathability, which greatly improves the procedure's chance for an optimal outcome."

The resheathable device features an 18 French delivery system which deploys a porcine pericardial valve mounted on a self-expanding nitinol stent. "As the average TAVI patient is typically older and often suffers from multiple comorbidities, these patients greatly benefit from the transfemoral approach used in the BIOVALVE trial," explained study investigator Henrik Treede, M.D., UKE, Hamburg. "The Biotronik TAVI device's ease of use means a simpler procedure and potentially fewer complications."

For more information:

Related Content

Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init